{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-026388","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.584775+00:00","generated_at":"2026-05-24T08:48:21.780944+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioXcel Therapeutics reaches 50% enrollment in SERENITY At-Home Phase 3 trial for BXCL501","bullets":["100 patients enrolled out of 200 expected (50% of total); 24 sites open as of March 20, 2025.","Trial evaluates BXCL501 (sublingual dexmedetomidine film) for acute agitation in bipolar disorder or schizophrenia at home.","Topline data expected in second half of 2025 to support sNDA for expanded IGALMI label.","Enrollment began September 2024; no safety or efficacy results reported yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-026388","json":"https://secwatch.observer/filing/0001104659-25-026388.json","markdown":"https://secwatch.observer/filing/0001104659-25-026388.md","text":"https://secwatch.observer/filing/0001104659-25-026388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925026388/0001104659-25-026388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925026388/tm259958d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:48:21.780944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}